ID Genomics Inc. news
ID Genomics, SPC today announced the completion of its first Pre-Submission meeting with the Food and Drug Administration for the CLoNeT E. coli Assay for Urinary Tract Infections (UTIs).
“We continue to make great strides in our development plans for the CLoNeT E. coli Assay,” said Linda Zuckerman, Ph.D., President and CEO. “This unique product will be able to detect the presence of E. coli, “fingerprint” or identify the clonal family that is present and
SEATTLE (March 29, 2017) Newly published, peer-reviewed results of observational clinical research have demonstrated that ID Genomics’ “bacterial fingerprinting” technology has the potential to improve antibiotic prescribing, reducing prescription errors and the overuse of broad-spectrum antibiotics, which could ultimately improve patient outcomes and slow the spread of antibiotic-resistant bacteria. The paper, “
The idea is simple: when a patient has a bacterial infection, doctors should find out what kind of bacteria it is so they can give the most effective treatment.
But growing bacteria in a lab to identify it takes hours to days. That means doctors have to make their best guess, and because there are dozens of possible strains, they guess wrong up to a third of the time.
Seattle biotech startup ID Genomics is develo
Antimicrobial resistance threatens the very core of human healthcare. ID Genomics’ Social Purpose is simple: to limit bacterial resistance and preserve antibiotics for the good of mankind.
We believe that antimicrobial resistance connects every human on the planet and that everyone has a right to be protected from this threat. While our core business focuses on developing diagnostics to guide precision antimicrobial selection at the point-of-care, we recognize
Today, Seattle-based ID Genomics, Inc.was awarded a grant from the Longitude Prize Discovery Awards, a seed funding program to help teams competing to win the prestigious Longitude Prize. Run by innovation foundation Nesta and supported by Innovate UK as funding partner, the